Evoke Pharma stock surges over 100%—here’s why

October 28, 2024 09:34 AM PDT | By Invezz

Evoke Pharma stock surges over 100%—here’s why — Image source: Invezz

Why does it matter for Evoke Pharma stock?

GIMOTI helped reduce all-cause visits to the emergency department in patients of DGP using GLP-1 receptor agonists by a whopping 91% in the aforementioned retrospective study that analysed a cohort comprising 92 patients.

Office visits and hospital outpatient visits saw a decline of 41% and 89% as well in the group on the company’s metoclopramide nasal spray.

The data that Evoke Pharma presented today is particularly significant considering a continued increase in the number diabetic patients on GLP-1 receptor agonists. Matt D’Onofrio – its chief executive said in a press release today:

This study combined with the earlier real-world data presented at key conferences, reinforces GIMOTI’s potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system.

Following today’s surge on the back of GIMOTI study results, Evoke Pharma stock has returned to the price at which it started this year (2024).

Other recent developments at Evoke Pharma

The announcement arrives shortly after Evoke Pharma secured about $3.0 million via exercise of warrants.

The company expects this new capital to help with commercialisation of GIMOTI.

In August, the Nasdaq-listed firm reported its financial results for the second quarter that missed Street estimates.

Evoke lost 93 cents a share on $2.55 million in revenue.

Analysts, in comparison, were at 6 cents per share only and $2.98 million, respectively.

At the time, CEO D’Onofrio told investors:

We are continuing to see growth in all phases of our business with increases in HCPs prescribing, patients taking GIMOTI, improvements in covered prescriptions with each showing our best performance in quarter over quarter growth in Q2.

Other notable developments at EVOK in recent weeks include appointment for Benjamin Smeal as a Class II director.

Smeal has previously held positions at Kenmare Management and Willet Advisors.

Note that Evoke Pharma is not a very widely covered stock among Wall Street analysts and it doesn’t pay a dividend at writing.

The post Evoke Pharma stock surges over 100%—here’s why appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.